do glp 1 drugs lower cholesterol Big News for Medicare Part D Patients! 🎉 Starting July 1, patients with Medicare Part D may qualify for GLP-1 medications (injection or oral) for as little as $50 per month. GLP-1 Stopping GLP-1 drugs can quickly

The investigation specifically showed that these drugs did not increase the risk of any fractures, confirming their safety profile in clinical practice ( 4.6 Ophthalmological effects 4.6.1 Glaucoma GLP-1R agonists exhibit anti-inflammatory and neuroprotective properties, suggesting they could also be beneficial in neurodegenerative diseases ( A recent registry-based case-control study, summarized in Table 2 , involving 1,961 patients found that the use of GLP-1R agonists is linked to a lower risk of glaucoma (Sterling et al., 2021 (79)

doi: 10.2337/db10-0474 158 JelsingJVrangNHansenGRaunKTang-ChristensenMKnudsenLB

Journal of Neuroscience

Phase I and II clinical trials conducted have shown improved cognitive and motor function with different drugs from GLP-1RA group although the small sized and limited duration of trials have not provided a conclusive result to influence the practice, although with further advancement in ongoing trials effects observed may be noteworthy for intervention in future practice (119)

NICE guidance (NG238) does not currently recommend GLP-1 receptor agonists specifically for dyslipidaemia treatment, though their cardiovascular benefits are recognised in appropriate patient populations

The results revealed that 180 patients developed acute pancreatitis and 108 patients developed pancreatic cancer